A Phase 3, Open-Label, Randomized Study of Sonrotoclax [BGB-11417] plus Zanubrutinib [BGB-3111] Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia (NCT07277231)

BGB-11417-304

This trial is Currently recruiting
Registration number NCT07277231
In patients with previously untreated chronic lymphocytic leukemia (CLL). The duration of each cycle is 28 days. Arm A: sonrotoclax + zanubrutinib up to 15 cycles. Arm B: venetoclax plus acalabrutinib up to 14 cycles.

Program & service

This trial is being run with the Cancer service, and as part of the Haematology program.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof Constantine Tam

Key inclusion data

Inclusion: ritux x4 for autoimmune cytopenia is allowed if at leaset 6 months. Neut 1.0 Plt 50, Or if BM involvement neut 0.75, plt 30 (without transfusion). Exclusion: CNS involvement. significant CVS. Activeinfection requiring systemic therapy. warfarin use, steriod, surgery in last 4 weeks. History of prior malignancy.

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.